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Abstract
Background: The German guideline on psychosocial interventions for people with severe mental disorders recommends a
broad spectrum of evidence-based treatments. Structured implementation of the associated patient version of the guideline is
missing to date. The study aims to assess whether structured implementation of a patient guideline improves the
empowerment of patients with severe mental disorders, as well as knowledge, attitudes and experiences regarding
psychosocial interventions, service use, treatment satisfaction, treatment needs, quality of life and burden of care.
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Methods: The study is a multicentre, cluster-randomised, controlled study with two parallel groups. Inpatients and day
hospital patients (all sexes; 18–65 years) with severe mental disorders will be included. Additionally, relatives of patients with
mental disorders (all sexes; ≥ 18 years) will be included. In the experimental group, the patient guideline will be
implemented using a multimodal strategy. Participants in the control group will receive treatment as usual but will be made
aware of the patient guideline. The primary outcome is the change of empowerment, assessed by using the
‘empowerment in the process of psychiatric treatment of patients with affective and schizophrenia disorders’ (EPAS) scale. In
addition, knowledge, attitudes and experiences regarding psychosocial interventions will be assessed as secondary
outcomes, as well as service use, satisfaction with care, patient need and quality of life and participation and social inclusion.
For relatives, the perceived burden of care also will be recorded. Results will be analysed using hierarchical linear models. For
the health economic evaluation, the incremental cost-utility ratios will be computed using the differences in total costs of
illness and the differences in quality-adjusted life years (QALY) between study groups.
Discussion: The study will be the first to assess the effects of a structured implementation of the patient version of a
psychiatric treatment guideline. The study has some limitations regarding the transferability of the results to other patients
and other regions. Furthermore, problems with the recruitment of patients and relatives and with the implementation of
intervention could occur during the study.
Trial registration: The study is registered in the German Clinical Trials Register (DRKS) and the WHO International Clinical
Trials Registry Platform (ICTRP) under registration number DRKS00017577 (Date of registration: 23 October 2019.
Keywords: Guideline, Implementation, Patient version, Cluster randomised controlled trial
Background
Psychosocial interventions aim to improve the ability of
individuals to live in their social environment and par-
ticipate in society [1]. They are a core component in the
treatment of persons with severe mental illness. A wide
range of very different psychosocial interventions exist,
e.g., occupational therapy, art therapy and supported
employment [1]. In 2012 the first version of the evi-
dence- and consensus-based (S3) guideline ‘Psychosocial
interventions in severe mental disorders’ of the German
Association for Psychiatry, Psychotherapy and Psychoso-
matics (DGPPN) was published and provided a compre-
hensive assessment and appreciation of the available
evidence on the efficacy of psychosocial interventions for
persons with severe mental illness [1]. In addition, an as-
sociated patient guideline that reproduces the recom-
mendations in plain language has been prepared to
promote active participation of the patients in their
treatment [2]. Both versions of the guideline were up-
dated in 2019 [1, 2]. However, evidence suggests that pa-
tients in Germany are informed insufficiently about
these interventions and that utilization rates are low [3].
Furthermore, at least in Germany, the uptake of psycho-
social interventions seems to depend more on regional
structures than on evidence [4].
While the pathway of evidence synthesis and guideline
development is sophisticated, evidence on the effects of
implementing treatment guidelines for mental illness in
clinical practice is sparse and inconsistent [5]. In par-
ticular, the effects of patient guidelines have not been
studied rigorously. Currently, no controlled study exists
that has put to test whether an implementation of a
psychiatric patient guideline has an influence on treat-
ment utilization or outcomes. Some encouraging evi-
dence of positive effects of patient information or
patient guidelines can be derived from studies using,
e.g., patient brochures in guideline implementation [6].
The present project aims to shed light on the effects of
a structured patient guideline implementation within a
multicentre, cluster-randomised, controlled, non-
blinded, superiority study with a 1:1 allocation.
Objectives
Primary objective
The primary objective is to assess, while using the ‘em-
powerment in the process of psychiatric treatment of pa-
tients with affective and schizophrenia disorders (EPAS)’
scale, whether a structured implementation of the pa-
tient guideline ‘Psychosocial interventions in severe
mental disorders’ improves the empowerment of pa-
tients with severe mental disorders with regard to their
treatment.
Other objectives
In addition, whether the structured implementation of
the patient guideline ‘Psychosocial interventions in se-
vere mental disorders’ is able to achieve the following is
also assessed:
1. improve knowledge, attitudes and experiences of
the patients and relatives about available treatments
2. improve service use by patients with severe mental
disorders
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3. improve treatment satisfaction of patients with
severe mental disorders and their relatives
4. change treatment needs and coverage of needs of
patients with severe mental disorders
5. improved quality of life of patients with severe
mental disorders and their relatives
6. cause the gain of one quality-adjusted life year
(QALY) in comparison to treatment as usual (TAU)
at a maximum willingness to pay (MWTP) thresh-
old of between 0 and 100.000 €
7. reduce the burden of care of relatives of patients
with severe mental illness
Methods/Design
This protocol describes a cluster-randomised controlled study,
which is the second part of a larger project that also includes a
cross-sectional study in the first part [7]. In the first part, an as-
sessment of the current status of the implementation of the S3
guideline recommendations for psychosocial interventions was
conducted. Furthermore, this cluster-randomised controlled
study will be supplemented by a separate qualitative study.
The protocol was prepared in accordance with the
SPIRIT statement (see Additional file 1) [8].
Study design and setting
The study is a multicentre, cluster-randomised, controlled,
non-blinded, superiority study with two parallel groups.
Randomisation will be performed as a stratified block ran-
domisation [9] with a 1:1 allocation (see ‘Randomisation’
section). Data will be collected in 10 clinics for psychiatry
and psychotherapy, which provide in- and outpatient psy-
chiatric care to the inhabitants of Upper Bavaria and Swa-
bia, Germany. The centres provide care for metropolitan
catchment areas (Augsburg and Munich), middle-urban
regions (Kempten and Memmingen) and rural regions
(Donauwörth, Günzburg, Kaufbeuren, and Taufkirchen).
Eligibility criteria
Inpatients and day hospital patients will be included if
they have a severe mental disorder according to the defin-
ition of the S3 guideline ‘Psychosocial interventions in se-
vere mental disorders’ (disease duration of ≥ 2 years and
substantial impact on activities of daily life) [1]. However,
in contrast to the S3 guideline, the inclusion criteria for
the present study will be limited to patients with schizo-
phrenia, schizotypal and delusional disorders (ICD-10
F2x) or mood [affective] disorders (ICD-10 F3x) to obtain
a more homogenous sample [10]. Considerable conse-
quences on the activities of daily life will be defined as a
‘Global Assessment of Functioning’ (GAF) [11] score ≤ 60
and a ‘Health of the Nation Outcome Scales’ (HoNOS)
[12] fulfilling one of two conditions: (a) a score of ≥ 2 on
one of the items of the subscale for symptomatic problems
(items 6, 7 and 8) and a score of ≥ 2 on each of the four
items of the subscale for social problems (items 9, 10, 11
and 12) or (b) a score of ≥ 3 on at least one of these items
(9, 10, 11 or 12). Patients of all sexes will be included if
they are between the ages of 18 and 65 years. Patients
need to have sufficient capacity to understand the research
project and to decide about their participation. In case of
doubts about the ability to obtain consent of the patient,
the responsible physician will decide on the capacity to
consent. Legal representatives of patients (if available) will
be informed about the study participation in case of con-
sent from the patient.
To include the perspective of relatives of patients with
mental disorders, relatives of all sexes will be included if
they are aged over 18 years and if they are capable of un-
derstanding the research project. Relatives will only be
included if they are not in current inpatient or day hos-
pital mental health care.
Recruitment procedure
The recruitment and data collection will be conducted
from October 2019 to March 2021. Eligible patients will
be approached and informed about the IMPPETUS study
by the study staff to determine whether they would be
willing to participate in the study, especially giving the
consent to be willing to participate at a time point 6
months after intervention (t2). If the patients give their
consent, a screening with the ‘Global Assessment of Func-
tioning’ (GAF) and the ‘Health of the Nation Outcome
Scales’ (HoNOS) will be carried out to identify patients
with severe mental illness according to the definition
above. The screening will be conducted as soon as pos-
sible after admission. For more details see Fig. 1.
Relatives will be addressed by the study staff in relatives
groups and made aware by posters/flyers at the hospitals.
Interventions
In centres randomised to the experimental group, the
patient guideline ‘psychosocial interventions in severe
mental disorders’ will be implemented using a multi-
modal strategy. The core component will be a two-part
group session for patients of more than 60-min duration
in which the contents of the patient guideline will be
clearly presented (e.g., with case examples). The group
session will be carried out jointly by the study staff (e.g.,
a psychologist) and a peer tutor (person with a lived ex-
perience of mental illness). The group sessions will also
pay attention to the availability of psychosocial interven-
tions in the regions but will not be limited to regional
offers. In addition, questionnaires and decision aids on
the basis of the patient guideline will be developed to as-
sist patients in their discussions with practitioners and to
promote their active demand for suitable psychosocial
therapies. Training for the use of the questionnaires and
decision aids will be provided in group sessions. Individual
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reminders will be developed. The two-part group sessions
will be offered weekly in the inpatient and day hospital
setting. Participation in both parts of the event will be sup-
ported by written information flyers. Repeated participation is
possible, but study participants should attend both parts at
least once. Furthermore, participants will receive the patient
guideline as a printed book. Essential contents of the patient
guideline will be made available on the Internet and will be
optimized for mobile use (www.thera-part.de). The group ses-
sions will include a brief introduction on how to use ‘Thera-
Part’. The plain language materials will be developed or tested
with the participation of representatives of patients and rela-
tives. A on-part information event for relatives will occur par-
allel to the two-part group events for the patients.
Patients in centres randomised to the control condi-
tion will receive treatment as usual but will be made
aware of the patient guideline ‘Psychosocial interven-
tions in severe mental disorders’ by receiving the same
guideline flyers as participants in the intervention group,
which summarises the key information of the guideline
and refers to additional sources of information. Treat-
ment as usual (TAU) was chosen as the control group to
compare the intervention with standard treatment. Partici-
pating relatives of patients in clinics randomised to the con-
trol condition will also receive the flyer for the guideline.
Prior to the start of the study, all study staff will re-
ceive comprehensive training on the implementation of
the assigned study conditions to ensure a consistent
Fig. 1 Flow of participants
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procedure across all sites. Regular retraining and super-
vision of the study staff will also take place. Regular ex-
change between all study staff and the study lead will
ensure compliance with the study protocol.
Outcomes and measurement
Patient-relevant outcomes and measurements
Primary outcome The primary outcome is the improve-
ment of empowerment (see objective 1) after 6 months,
which will be measured as change according to the ‘em-
powerment in the process of psychiatric treatment of pa-
tients with affective and schizophrenia disorders’ (EPAS)
scale [13]. The scale comprises a basic module with 33
items, which include the five dimensions ‘everyday cop-
ing‘, ‘social relationships‘, ‘treatment participation‘ and
‘hope and self-efficacy‘. Two add-on modules also cover
empowerment in the care of underage children and at
work. The questionnaire, whose psychometric properties
have been successfully tested in a field study [13], pro-
vides a comprehensive record of empowerment in the
psychiatric treatment process. Patients and their relatives
will be interviewed with the EPAS.
Other outcomes Changes in patient knowledge, atti-
tudes and experiences regarding available treatments
(see objective 2) will be assessed using a checklist devel-
oped for this study. The checklist includes all psycho-
social interventions of the S3 guideline ‘psychosocial
interventions’ (can be provided on request) and address
the following:
1. Changes in service use (see objective 3) will be
measured as changes on the German version of the
‘Client Sociodemographic and Service Receipt
Inventory’ (CSSRI) [14]. The CSSRI is a semi-
structured interview to assess social and demographic
data, accommodation data, detailed information re-
garding treatment, professional visits and social and
health service utilisation for estimating healthcare
costs. Additionally, the CSSRI systematically records
the use of psychiatric, medical, psychosocial and re-
habilitative health services (direct costs) and product-
ivity losses (indirect costs) and therefore completely
covers the costs of the disease from an economic per-
spective. Therefore, the health economic evaluation
(see objective 6) will be based on the data collected
with the CSSRI. An appropriate pre-structuring of
the requested health care services will ensure that the
receipt of the psychosocial care services recom-
mended in the S3 guideline ‘Psychosocial interven-
tions’ will be assessed.
2. Satisfaction with treatment (see objective 4) of the
patients will be assessed with the German
satisfaction questionnaire ‘ZUF-8’ [15]. The ZUF-8
has eight items and is a one-dimensional measure
of satisfaction to record the general or overall pa-
tient satisfaction with the treatment received. The
item values are summed. High scale values indicate
a large level of satisfaction and low scale values a
low ‘satisfaction‘ (range from 8 to 32).
3. Changes in patient treatment needs and coverage of
needs (see objective 5) will be assessed by using the
German version of the ‘Camberwell Assessment of
Need’ (CAN-EU) [16, 17]. The CAN-EU assesses 22
domains of potential individual care needs. Each do-
main is rated on a 3-point scale from the absence of
need (= 0) to the presence of an unmet need (= 2). A
total score is calculated by adding the domain ratings.
4. Quality of Life (QoL; see objective 6) of the patients
will be measured with the German version of the
World Health Organization’s Quality of Life
Instrument-abbreviated version (WHOQOL-BREF)
[18, 19]. The WHOQOL-BREF is a tool with 26
items: 24 items in four domains: physical (seven
items), psychological (six items), social (three items)
and environmental (eight items), and two additional
items: the overall quality of life (item 1) and level of
satisfaction with health (item 2). The items are
rated on a five-point Likert-type scale. To calculate
domain scores, the mean of all items within a do-
main is multiplied by four. Subsequently, these raw
domain scores are transformed into a scale from 0
to 100 points (to enable comparisons to be made
between domains composed of unequal numbers of
items), with higher scores denoting better QOL.
5. The calculation of quality-adjusted life years
(QALYs; see objective 7) will be based on the Ger-
man Version of the EuroQol (EQ-5D-5 L) [20–22].
The EQ-5D-5 L generates health states at five di-
mensions as a basis for the generation of QALYs.
The EQ-5D-5 L questionnaire includes five ques-
tions on current issues in the dimensions of ‘mobil-
ity‘, ‘self-care‘, ‘usual activities‘, ‘pain/discomfort‘
and ‘anxiety/depression‘. Five possible answers exist
for each dimension: (1) no problems, (2) slight
problems, (3) moderate problems, (4) severe prob-
lems and (5) unable to do. QALYs will be generated
by means of the German value set [23].
6. In addition, the participation and social
inclusion of the patients will be assessed using
the German questionnaire ‘Fragebogen zur
Erfassung sozialer Partizipation und sozialer
Inklusion chronisch psychisch erkrankter
Menschen’ (F-INK) [24]. The F-INK measures
the participation and social inclusion of individ-
uals with a chronic mental disorder. It is a
modular questionnaire with nine modules that
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assess the central dimensions of social inclusion
[24].
7. Sociodemographic data of the patients (e.g., sex, age
and socioeconomic data) and patient medical
history will be assessed within the CSSRI. The
patient’s medical history (diagnosis, length of illness,
length of current disease episode, number of
previous episodes and current somatic and
psychotherapeutic treatment) will be derived from
the patient or the patient’s record data.
Relatives—relevant outcomes and measurements
Relevant outcomes and measurements for relatives in-
clude the following:
1. The mental disorder, the disorder severity and the
restrictions in daily life of the participants’ mentally
ill relatives will be assessed with a separate
questionnaire.
2. Changes in the relatives’ knowledge, attitudes and
experiences regarding available treatments (see
objective 2) will be evaluated using the same
developed checklist that was used for patients.
3. Satisfaction with treatment (see objective 4) from
the perspective of the relatives will be assessed with
the ZUF-8 (see above).
4. Changes in treatment needs and coverage of needs
of the mentally ill relatives (see objective 5) will be
assessed by using the CAN-EU (see above).
5. Quality of Life (QoL) of relatives of patients with
severe mental illness (see objective 6) will be
measured with the WHOQOL-BREF (see above).
6. Relatives’ burden of care (see objective 8) will be
assessed using the ‘Burden Assessment scale’ (BAS)
[25]. The BAS is a 19-item scale that focuses on
specific subjective and objective consequences of
relatives caring for persons with severe mental dis-
orders within the past 6 months. Answers are given
on a 4-point Likert scale ranging from (1) not at all
to (4) very much, with higher values indicating
stronger burden.
7. Sociodemographic data of the relatives will be
assessed with a separate questionnaire.
Data collection and management
Patients and relatives will be interviewed by the study
staff at three time points: shortly after admission (base-
line, t0), 2 weeks after visiting both parts of the group
sessions (intervention group) or 6 weeks after t0 (control
group) (t1), and 6 months after t0 (t2, both groups) (see
Table 1). Due to the large number of outcomes to be
measured, the interview can, if necessary, be divided into
several appointments in order to avoid excessive de-
mands on the participants. The collected data will be
recorded on paper and subsequently entered in a stan-
dardized data form at the recruiting centres. Data entry
will be done by one study member and checked by an-
other member (double check) to avoid mistakes. Data
will be stored in a secured computerised database cen-
trally at the study centre Günzburg. Participant files will
be maintained in storage for a period of 10 years after
completion of the study.
To avoid follow-up losses, study staff will contact the
participants regularly, for example by visiting the sub-
jects during their inpatient stay. After discharge, they
will be informed by newsletter and will be informed by
phone or (e)-mail about upcoming data collection. Fur-
thermore, the participants will be offered interview ap-
pointments after discharge that can be carried out at the
participant’s home or by telephone.
Participants may withdraw from the study for any rea-
son at any time. Participants who do not follow the
intervention schedule will be interviewed as scheduled
during the follow-up appointments. If possible, reasons
for dropout are recorded.
Data monitoring
A data monitoring committee was not established be-
cause no risks are to be expected for the participants in
the intervention or the control group.
Quality control
Prior to the start of the study, the study staff in all recruit-
ing clinics will receive comprehensive assessment training.
This rigorous training and regular meetings during the re-
cruitment phase will ensure adherence to the protocol by
all researchers involved in the study. During all study
phases, the study lead will supervise the study.
Sample size
Sample size calculation was based on a two-step proced-
ure due to the hierarchical data structure. In the first
step, the sample size for an individual randomized study
is calculated. Based on studies using the ‘empowerment in
the process of psychiatric treatment of patients with affective
and schizophrenia disorders (EPAS)’ scale [26], a medium ef-
fect (0.4 SD units) of the implementation intervention on the
primary endpoint is expected. This effect is detectable with
an error probability of 5% (alpha) and a power of 80% by a t-
test for independent samples with a sample size of 2 × 100
participants (200 in total).
The second step takes the cluster structure of the data
into account. We assume that each centre recruits 35 pa-
tients (m) on average. The design effect (DE) is needed for
the inflation of the group sample size: DE = 1 + (m - 1) *
ICC with the fixed cluster size m and the intra-cluster cor-
relation coefficient ICC. We assume a liberal intra-class
correlation coefficient of 0.02 to control for the correlation
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of the outcome of participants of the same centre.
Thereby, the DE is 1 + (35–1) * 0.02 = 1.68, which gives a
sample size of 200 × 1.68 = 336 patients. As every centre
recruits 35 patients on average, 10 centres are needed for
the trial. Due to the severity of the disease in the patient
population, case number planning assumes that 70% of
patients can be reached 6months after t0, so that an over-
sampling to (35/0.7) 50 patients per study centre will be
recruited, resulting in 10 centres * 50 patients = 500 par-
ticipants (2 × 250) as the overall sample size. This 70%
estimate is based on experiences at the Günzburg site
from three studies conducted with similar populations
[27–29].
Randomisation
The randomisation of the centres (cluster) to the
intervention or control group will be done externally
by the Institute for Epidemiology and Medical Biom-
etry, Ulm University, Ulm, Germany, by a stratified
block randomisation. The 10 recruiting centres will
Table 1 Template for the schedule of enrolment, interventions and assessments
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be randomised 1:1 to the intervention and control
group using the size of centre (small, large) as strata.
The random assignment will be performed by the
randomisation program ROM [9].
Statistical methods
First, the sociodemographic and clinical characteristics
will be listed. Categorical variables will be described as
absolute and relative frequencies and with graphical rep-
resentation (e.g., bar chart). Continuous variables will be
described by means and SDs, supplemented by mini-
mum, median, percentiles and maximum. In addition,
data will be analysed graphically (e.g., boxplot). Number
of missing values will be reported for all variables of
interest. Cases with missing values will be compared
with those with complete data with regard to character-
istics relevant for study outcomes.
The primary outcome is the improvement of em-
powerment 6 month after t0 (EPAS-t2) compared to
baseline (EPAS-t0). Therefore, a hierarchical linear
model (mixed model approach [30, 31]) is used to
model EPAS-t2 as outcome and intervention, baseline
EPAS-t0, centre and centre-size as main regressors
with special attention to the intervention (confirma-
tory). The significance level will be set to 5% for
intervention. The analysis will be based on a modified
intention-to-treat (modITT)-population, using all pa-
tients with an outcome at month six (EPAS-t2) [32],
since an imputation of the primary outcome can be
misleading. Data management procedures will be im-
plemented to reduce the drop-out rates; thus, a rela-
tively low drop-out rate is expected. To examine a
possible selection bias, the baseline data of ITT and mod-
ITT populations will be compared. In case of differences,
these variables will be included in the regression models
to adjust for confounding. For the independent variables,
mixed model approaches can handle missing data well,
and thus, no multiple imputation is needed in particular.
However, according to this modITT concept, multiple im-
putation [33] of missing data in independent variables will
be conducted by fully conditional specification (FCS) to
perform a sensitivity analysis.
Other possible confounders with respect to the main
outcome will be investigated by adding them into the
model, eventually using backward selection procedures
for variable selection and multiple imputations (see
above). These analyses will be subjected to explorative
interpretation only.
All other outcomes (see chapter ‘Outcomes and meas-
urement’) will be analysed in a similar way. Subgroup
analyses will be conducted separated by recruiting cen-
tres. Patient-related analyses (knowledge, attitudes, and
experiences, service use, satisfaction with treatment,
treatment needs and quality of life) will be conducted
separately for patients with F2x and F3x diagnoses in
additional subgroup analyses. Other categorisations
based on quantitative variable are not planned.
Health economic evaluation (HEA) will be conducted
from the societal and from the payer (statutory health
insurance) perspective. Incremental cost-utility ratios
(ICUR) will be computed using the differences in total
(direct and indirect) costs of illness and the differences
in quality-adjusted life years (QALY) between study
groups over 12 months for the societal perspective. For
the HEA from the payer perspective only the direct costs
reimbursed by the statutory health insurance will be
used as ICUR numerator. For both perspectives the sto-
chastic uncertainty of the ICUR will be estimated by
means of nonparametric bootstrapping with 2000 repli-
cations [34]. Probability of cost-effectiveness at MWTP
for the gain of one QALY in the range between 0 and
100,000 € will be estimated for both perspectives by
means of the cost-effectiveness acceptability curve [34].
The calculation of the QALY is based on the EQ-5D-5 L
by means of the German value set [23].
All analyses will be conducted separately for patients
and relatives.
Ancillary and post-trial care
The subjects enjoy insurance protection while participat-
ing in the research project. The Ulm University Hospital
and its employees involved in the study (study doctors,
other staff) are covered by liability insurance if the test
subjects are harmed through their fault. The subjects are
also insured for accidental travel to and from the study
centre.
Amendments
In the event of protocol amendments, the date of each
amendment will be accompanied by a description of the
change and the rationale.
Sponsor
Ulm University Medical Centre, Albert-Einstein-Allee 29,
89,081 Ulm, Germany is the trial sponsor. The sponsor is
not involved in the design of the study, manuscript writing
or collection of data, and the sponsor will not be involved
in data analysis or interpretation and manuscript writing
in the future.
Dissemination
The results of this protocol study will be published in
peer-reviewed journals as well as at national and inter-
national conferences. A publication and authorship agree-
ment between all project partners was agreed, which
regulates the procedure for publications in detail.
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Access to data
Principal Investigators will be given access to the cleaned
data sets under conditions defined in the publication
agreement. Analysis data sets do not contain identifying
participant information.
Discussion
This study is the first to assess the effects of a structured
implementation of a patient version of a psychiatric
treatment guideline. The results will shed light on the ef-
fects of a structured implementation of such patient
guidelines and will provide insights how patients guide-
lines can be implemented.
Some limitations of the study should be noted. For ex-
ample, recruitment will take place in clinics; thus, only
patients with inpatient stays will be recorded. Further-
more, the assessment is limited to south-east Germany
(Bavaria), so transferability of the results to other regions
needs to be considered. In addition, the study will not
cover the full range of patients with severe mental disor-
ders, such as severe personality disorders (F60 - F61),
severe anxiety disorders (F41) or severe obsessive-
compulsive disorder (F42).
In addition, an imbalance may occur in the recruit-
ment numbers between the two randomised groups, as
the recruitment of subjects in one of the two groups
could be more difficult than in the other (e.g., if the
subjects do not want to participate without interven-
tion). Therefore, the extension of the recruitment
period may be necessary for one group to reach com-
parable sample sizes.
In the intervention group, difficulties may occur in main-
taining the participation for both group sessions.
Furthermore, recruiting relatives may be difficult be-
cause relatives are often not easily accessible.
Trial status
Protocol Version: 1.3, Date: 14. October 2019;
Date of first enrolment: 28. October 2019;
Estimated date of the end of recruitment: 31. March 2021.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/1
0.1186/s13063-020-4200-z .
Additional file 1. SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents.
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MWTP: Maximum willingness to pay; QALY: Quality-adjusted life year; S3
guideline: Evidence and consensus-based guideline; SD: Standard deviation;
t0: Assessment shortly after admission (baseline); t1: Assessment 2 weeks after
visiting both parts of the group sessions (intervention group) or 6 weeks
after t0 (control group); t2: Assessment 6 months after t0; TAU: Treatment as
usual; WHOQOL-BREF: World Health Organization’s Quality of Life Instrument-
abbreviated version; ZUF-8: German satisfaction questionnaire
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